MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/joim.13498

Медицинская библиотека · Journal of internal medicine · 2022

Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.

Ingason Arnar B, Rumba Edward, Hreinsson Johann P, Agustsson Arnar S, Lund Sigrun H, Palsson Daniel A, Reynisson Indridi E, Gudmundsdottir Brynja R, Onundarson Pall T, Tryggvason Geir, Bjornsson Einar S

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Although epistaxis is one of the most common side effects of oral anticoagulation, it is unclear whether epistaxis rates vary between different oral anticoagulants (OAC).

OBJECTIVE

To compare rates of clinically relevant epistaxis between OAC.

METHODS

Epistaxis event rates were compared between new users of apixaban, dabigatran, rivaroxaban, and warfarin in a nationwide population-based cohort study over a 5-year study period, 2014-2019. Data was collected from the Icelandic Medicine Registry and the five major hospitals in Iceland. Inverse probability weighting (IPW) was used to yield balanced baseline characteristics, and epistaxis rates were compared using Kaplan-Meier survival estimates and Cox regression.

RESULTS

During the study period, 2098 patients received apixaban, 474 dabigatran, 3106 rivaroxaban, and 1403 warfarin. In total, 93 patients presented with clinically relevant epistaxis, including 11 (12%) major epistaxis events and one fatal epistaxis episode. Furthermore, seven patients (9%) with non-major epistaxis later presented with major bleeding during the follow-up period. Warfarin use was associated with higher rates of epistaxis compared to apixaban (2.2 events per 100-person years (events/100-py) vs. 0.6 events/100-py, hazard ratio [HR] 4.22, 95% confidence interval [CI] 2.08-8.59, p < 0.001), rivaroxaban (2.2 events/100-py vs. 1.0 events/100-py, HR 2.26, 95% CI 1.28-4.01, p = 0.005), and dabigatran (2.2 events/100-py vs. no events, HR n/a, p < 0.001).

CONCLUSION

Warfarin treatment was associated with higher rates of clinically relevant epistaxis compared to direct oral anticoagulants.

Для цитирования: Ingason Arnar B, Rumba Edward, Hreinsson Johann P, Agustsson Arnar S, Lund Sigrun H, Palsson Daniel A, Reynisson Indridi E, Gudmundsdottir Brynja R, Onundarson Pall T, Tryggvason Geir, Bjornsson Einar S. Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.. Journal of internal medicine. 2022. DOI: 10.1111/joim.13498.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.